The roles of different forms of IL-15 in human melanoma progression.
IL-15
IL–15 complex
cytokines
immunology
melanoma
natural killer cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
03
2023
accepted:
05
05
2023
medline:
20
6
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Melanoma is a lethal skin cancer, and the risk of developing it is increased by exposure to ultraviolet (UV) radiation. The production of cytokines such as interleukin-15 (IL-15), induced by the exposure of skin cells to UV rays, could also promote melanoma development. The aim of this study is to investigate the possible role of Interleukin-15/Interleukin-15 Receptor α (IL-15/IL-15Rα) complexes in melanoma development. The expression of IL-15/IL-15Rα complexes by melanoma cells was evaluated both Analysis of a melanoma tissue microarray shows a significant increase in the number of IL-15 Membrane-bound and secreted IL-15/IL-15Rα complexes are continuously present during progression in melanoma. It is notable that, although IL-15/IL-15Rα initially promoted the production of cytotoxic T and NK cells, at stage IV promotion of the development of anergic and dysfunctional cytotoxic NK cells was observed. In a subgroup of melanoma metastatic patients, the continuous secretion of high amounts of the soluble complex could represent a novel NK cell immune escape mechanism.
Sections du résumé
Background
Melanoma is a lethal skin cancer, and the risk of developing it is increased by exposure to ultraviolet (UV) radiation. The production of cytokines such as interleukin-15 (IL-15), induced by the exposure of skin cells to UV rays, could also promote melanoma development. The aim of this study is to investigate the possible role of Interleukin-15/Interleukin-15 Receptor α (IL-15/IL-15Rα) complexes in melanoma development.
Methods
The expression of IL-15/IL-15Rα complexes by melanoma cells was evaluated both
Results
Analysis of a melanoma tissue microarray shows a significant increase in the number of IL-15
Conclusions
Membrane-bound and secreted IL-15/IL-15Rα complexes are continuously present during progression in melanoma. It is notable that, although IL-15/IL-15Rα initially promoted the production of cytotoxic T and NK cells, at stage IV promotion of the development of anergic and dysfunctional cytotoxic NK cells was observed. In a subgroup of melanoma metastatic patients, the continuous secretion of high amounts of the soluble complex could represent a novel NK cell immune escape mechanism.
Identifiants
pubmed: 37334356
doi: 10.3389/fimmu.2023.1183668
pmc: PMC10272795
doi:
Substances chimiques
Antineoplastic Agents
0
Interleukin-15
0
Interleukin-15 Receptor alpha Subunit
0
IL15 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1183668Informations de copyright
Copyright © 2023 Di Matteo, Munari, Fiore, Santopolo, Sampaoli, Pelosi, Chouaib, Tumino, Vacca, Mariotti, Ebert, Machwirth, Haas, Pezzullo, Pietra, Grottoli, Buart, Mortier, Maggi, Moretta, Caruana and Azzarone.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Oncol. 2018 May;19(5):694-704
pubmed: 29628312
Front Immunol. 2020 Jan 09;10:3010
pubmed: 31998304
Oncogene. 2000 Oct 26;19(45):5153-62
pubmed: 11064452
Arch Dermatol Res. 2000 Jul;292(7):348-53
pubmed: 10966059
Psoriasis (Auckl). 2020 Aug 20;10:23-28
pubmed: 32944566
J Biol Chem. 1995 Dec 15;270(50):29862-9
pubmed: 8530383
Clin Cancer Res. 2018 Jul 1;24(13):3036-3045
pubmed: 29599411
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21647-52
pubmed: 21098276
J Immunol. 2008 Jun 15;180(12):7818-26
pubmed: 18523245
Oncoimmunology. 2018 Dec 25;8(3):1557030
pubmed: 30723590
J Exp Med. 2005 Oct 3;202(7):907-12
pubmed: 16203864
Cancer Res. 2018 Jul 15;78(14):3913-3925
pubmed: 29752261
J Immunol. 2016 Jun 1;196(11):4544-52
pubmed: 27183627
Front Cell Infect Microbiol. 2020 Feb 13;10:49
pubmed: 32117816
Oncogene. 1998 May 14;16(19):2503-12
pubmed: 9627116
Immunity. 2002 Nov;17(5):537-47
pubmed: 12433361
Am J Clin Exp Immunol. 2020 Jun 15;9(3):10-21
pubmed: 32704430
Photodermatol Photoimmunol Photomed. 2000 Apr;16(2):67-73
pubmed: 10823315
Mol Cancer Ther. 2009 Sep;8(9):2736-45
pubmed: 19723883
Oncoimmunology. 2016 Dec 7;6(2):e1261242
pubmed: 28344869
J Clin Med. 2019 Oct 16;8(10):
pubmed: 31623224
Cell. 2019 Feb 7;176(4):775-789.e18
pubmed: 30595452
Inflamm Res. 2020 Mar;69(3):245-254
pubmed: 31989191
J Pediatr Surg. 2013 Nov;48(11):2207-13
pubmed: 24210187
Clin Cancer Res. 2011 Aug 15;17(16):5343-52
pubmed: 21737507
Proc Natl Acad Sci U S A. 2013 May 14;110(20):8158-63
pubmed: 23637340
JCI Insight. 2018 Feb 8;3(3):
pubmed: 29415897
Front Immunol. 2021 Jul 22;12:711621
pubmed: 34367174
Front Immunol. 2019 Jun 04;10:1242
pubmed: 31214193
J Immunol. 1995 Nov 1;155(9):4492-6
pubmed: 7594612
J Allergy Clin Immunol. 2021 Jan;147(1):349-360
pubmed: 32417134
J Immunol. 2004 Apr 1;172(7):4225-34
pubmed: 15034035
Oncoimmunology. 2012 Sep 1;1(6):974-975
pubmed: 23162776
J Interferon Cytokine Res. 2023 Jan;43(1):2-22
pubmed: 36651845
J Immunol. 2015 Sep 1;195(5):2353-64
pubmed: 26216888
Int J Cancer. 2019 Sep 15;145(6):1660-1668
pubmed: 30856277
Crit Rev Oncog. 2014;19(1-2):133-41
pubmed: 24941379
Nature. 2019 Jan;565(7739):366-371
pubmed: 30598548
Biol Open. 2019 Feb 1;8(2):
pubmed: 30709842
Int J Cancer. 1998 Feb 9;75(4):517-24
pubmed: 9466650
Sci Rep. 2016 Oct 12;6:35067
pubmed: 27731361
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33203664
J Biol Chem. 2006 Jan 20;281(3):1612-9
pubmed: 16284400
J Immunol. 2018 Jul 15;201(2):493-506
pubmed: 29848756
Blood. 2005 Oct 1;106(7):2302-10
pubmed: 15976182
J Clin Oncol. 2007 Apr 10;25(11):1363-8
pubmed: 17416855
Expert Rev Clin Immunol. 2014 Dec;10(12):1689-701
pubmed: 25359408
J Biol Chem. 2007 Dec 21;282(51):37191-204
pubmed: 17947230
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7513-8
pubmed: 19383782
Sci Immunol. 2017 Apr 14;2(10):
pubmed: 28738020
J Biol Chem. 2012 Nov 23;287(48):40328-38
pubmed: 23074221
J Clin Oncol. 2005 Jul 20;23(21):4735-41
pubmed: 16034049
Clin Respir J. 2017 Nov;11(6):789-796
pubmed: 26619201
Cancer Cell. 2017 Aug 14;32(2):135-154
pubmed: 28810142
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):599-608
pubmed: 30587590
J Natl Cancer Inst. 2011 Dec 21;103(24):1884-98
pubmed: 22043039
Blood. 2012 Jul 5;120(1):e1-8
pubmed: 22496150
Eur J Immunol. 2012 Jul;42(7):1833-42
pubmed: 22585684
J Clin Invest. 2019 Jun 18;129(9):3770-3785
pubmed: 31211698
PLoS One. 2015 Mar 10;10(3):e0120274
pubmed: 25756182
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4240-6
pubmed: 15557426
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33452207
Neoplasia. 2015 Jun;17(6):509-17
pubmed: 26152359